MedTrace Logo

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy

NCT06290856 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2026-01-29

No results posted yet for this study

Summary

Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. They want to evaluate the ctDNA assays on a fully automated "low-cost" multiplex platform which is already implemented in routine molecular diagnostics of solid biopsies. The project will evaluate to what extent these ctDNA assays are relevant for clinical decision-making.

Conditions

Interventions

DIAGNOSTIC_TEST

Multiplex PCR-test for circulating tumor DNA

All recruited patients will be tested for

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Ragnhild Nome, MD,PhD · Oslo University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2024-07-15
Completion
2024-07-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06290856 on ClinicalTrials.gov